Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF.
The aim of this study was to find the minimal effective daily s.c. dose of the gonadotrophin-releasing hormone (GnRH) agonist, triptorelin acetate, that suppresses the GnRH-induced release of luteinizing hormone (LH) at time of human chorionic gonadotrophin (HCG) injection and thereby prevents spontaneous LH surges during in-vitro fertilization (IVF) stimulation cycles. Therefore, a double-blind, prospective and randomized titration study was performed. A total of 48 IVF patients were divided into four groups of 12 patients. Each group received a different dose of triptorelin acetate, namely 5, 15, 50 or 100 microg s.c. daily. Standard ovarian stimulation was carried out using urinary follicle stimulating hormone (FSH) preparations. A 500 microg GnRH test was performed 90 min before the HCG injection in order to measure the degree of pituitary desensitization. Spontaneous LH surges were not detected in any of the groups, although three patients in the 5 microg group had ovulated at the time of ovum retrieval. The pituitary LH response to the GnRH test at time of HCG, expressed as area under the curve (AUC), appeared to be dose-dependent. Thus, a daily s.c. dose of 100 microg triptorelin acetate appears to be too high, since adequate desensitization of the pituitary (i.e. no spontaneous LH surge) can be achieved with doses as low as 15 and 50 microg.
Janssens
R M
RM
Institute for Endocrinology, Reproduction and Metabolism, IVF Center, Free University Hospital, Amsterdam, The Netherlands. R.Janssens@AZVU.NL
Vermeiden
J P
JP
Lambalk
C B
CB
Schats
R
R
Schoemaker
J
J
D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism; D008186:Luteolytic Agents / Q000008:administration & dosage*; D010062:Ovulation Induction; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism; D011247:Pregnancy; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
D006063:Chorionic Gonadotropin; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone